Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.55 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.38 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399086 | 1.00 | GRIN2B (0.55) | GRIN2BAPPMAPTALDH1A1GAA | |
| SCHEMBL1399138 | 0.91 | APP (0.44) | GRIN2BAPPMAPTALDH1A1GAA | |
| SCHEMBL1399136 | 0.91 | APP (0.44) | GRIN2BAPPMAPTALDH1A1GAA | |
| SCHEMBL1399059 | 0.77 | MAPT (0.58) | GRIN2BAPPMAPTALDH1A1GAA | |
| SCHEMBL1399058 | 0.77 | MAPT (0.58) | GRIN2BAPPMAPTALDH1A1GAA | |
| SCHEMBL1399049 | 0.73 | F2R (0.39) | APPMAPT | |
| SCHEMBL1399051 | 0.73 | F2R (0.39) | APPMAPT | |
| SCHEMBL1399035 | 0.71 | F2R (0.44) | MAPTALDH1A1 | |
| SCHEMBL1399105 | 0.71 | GAA (0.47) | MAPTALDH1A1GAA | |
| SCHEMBL1399107 | 0.71 | GAA (0.47) | MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046748-B1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PF MEDICAMENT (FR) | 2011-03-02 | — | — | EP | claimed |
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-07 | — | — | US | claimed |
| EP-2046748-B1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PF MEDICAMENT (FR) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | F2R, F2RL1, FPR1 | GRIN2B 2264/4885APP 1442/4885MAPT 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.